Computational PharmacologyStructural Biology & DockingConfidential

Mitragyna Alkaloids: Opioid Receptor Subtype Docking & Stereochemical Dynamics

In silico molecular docking of mitragynine and related natural alkaloids against human delta (OPRD1) and kappa (KOR) opioid receptors with redocking validation and stereocenter refinement.

STATUSConfidential

STARTEDAug 2023

FIELDComputational Pharmacology

KEYWORDSMitragynine, Opioid Receptors, Molecular Docking, Structural Biology, Stereochemistry, AutoDock Vina

TOOLSAutoDock Vina / Smina, Open Babel, Python, Snakemake, BIOVIA Discovery Studio, PyMOL

THE QUESTION

How do natural stereoisomeric configurations of mitragynine and related indole alkaloids modulate binding postures and conserved Asp3.32 salt-bridge interactions across delta (OPRD1) and kappa (KOR) opioid receptors?

BACKGROUND

Mitragyna speciosa (kratom) produces distinct indole and spiro-oxindole alkaloids that exert atypical opioid analgesic activity with reduced respiratory depression. Evaluating their therapeutic mechanism requires atomic-resolution receptor-ligand docking against validated high-resolution crystal structures of human opioid receptors (OPRD1 and KOR), verified against prototypical agonists and clinical antagonists.

Mitragyna speciosa leaves and alkaloid chemical structures

APPROACH OVERVIEW

CRYSTAL STRUCTURE CURATION & QC

Prepared human OPRD1 (PDB: 6PT3) and KOR (PDB: 4DJH) binding pockets, stripped water molecules, and mapped grid coordinates.

STEREOCHEMICAL ISOMERIC PREPARATION

Sourced curated PubChem Isomeric SMILES (mitragynine CID 3614, rhynchophylline CID 5281423), protonated at physiological pH 7.4 (MMFF94).

REDOCKING RMSD BENCHMARKING

Re-docked co-crystallized native ligands (DPI-287 and JDTic), achieving crystallographic fidelity (RMSD 1.19 A and 0.41 A).

HIGH-EXHAUSTIVENESS DOCKING

Simulated binding postures of test alkaloids and 7 reference opioid controls (Morphine, Naloxone, Naltrindole, SNC-80, U-50488) at exhaustiveness 32.

CONSERVED ASP3.32 INTERACTION PARSING

Calculated spatial proximity to conserved catalytic residues (Asp128 on OPRD1 and Asp138 on KOR).

METHODS

•Target Receptors: Human Delta Opioid Receptor (OPRD1, PDB: 6PT3 at 2.80 A) and Kappa Opioid Receptor (KOR, PDB: 4DJH at 2.90 A).
•Ligand Cohort: Test alkaloids (Mitragynine, Rhynchophylline, Deacetylvindoline), negative control (Na-Diclofenac), and 6 standard opioids.
•Docking Engine: Smina / AutoDock Vina with exhaustiveness = 32, grid dimension = 20x20x20 A, and energy range = 3.0 kcal/mol.
•Stereochemical Optimization: Open Babel MMFF94 energy minimization with explicit 3D isomeric stereocenters (E-alkene and chiral bridgeheads).
•Validation Standard: Native co-crystallized ligand redocking required crystallographic RMSD <= 2.0 A.

KEY DATA SNAPSHOT

OPRD1 REDOCKING RMSD1.19 ADPI-287 NATIVE (< 2.0 A)

KOR REDOCKING RMSD0.41 AJDTic NATIVE (< 2.0 A)

DOCKING EXHAUSTIVENESS32HIGH-FIDELITY SAMPLING

RESULTS

PubChem isomeric stereochemical refinement established that mitragynine and related alkaloids engage the conserved catalytic Asp3.32 residue on both KOR and OPRD1 via key salt-bridge interactions, closely mirroring the binding postures of clinical opioid controls while demonstrating receptor subtype selectivity.

DISCUSSION

Correcting non-isomeric representations to authentic PubChem isomeric SMILES is essential: the natural E-alkene configuration enables stable positioning in the morphinan-binding pocket.

Mitragynine and rhynchophylline engage the conserved Asp3.32 residue (Asp128 in OPRD1, Asp138 in KOR), which is universally recognized as the essential anchor for opioid receptor activation.

Alkaloid stereoisomers demonstrate distinct affinity patterns for KOR, supporting ethnobotanical reports of analgesic and sedative synergies in multi-alkaloid botanical extracts.

LIMITATIONS

•Static grid-based molecular docking does not capture downstream G-protein versus beta-arrestin-2 functional bias pathways without molecular dynamics (MD) simulations.
•Alkaloid pharmacokinetics and blood-brain barrier (BBB) permeability require complementary in vivo validation.

IMPACT & APPLICATION

Scientific ManuscriptFull research manuscript detailing receptor docking and stereochemical dynamics currently under journal review.

Opioid Structural Biology LeadAtomic coordinates resolving non-morphinan alkaloid binding modes at human opioid receptors.

Reproducible Snakemake PipelineAutomated end-to-end command line receptor preparation, docking, and interaction scoring workflow.

DATA & REPRODUCIBILITY

Analytical code and specific target coordinates are currently held under institutional review and confidential protocol.

PIPELINE ARCHITECTUREAutomated command-line receptor preparation and docking workflow

INSTITUTIONAL ACCESSConfidential research project — complete 3D docking complexes and interaction matrices held under pre-publication protocol

REFERENCES

01Che, T. et al. (2020). Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. Cell, 172(1), 55–67.
02Wu, H. et al. (2012). Structure of the human kappa-opioid receptor in complex with JDTic. Nature, 485(7398), 327–332.
03Kruegel, A. C. et al. (2016). Synthetic and receptor signaling explorations of the Mitragyna alkaloids: Mitragynine as an atypical and safer opioid. JACS, 138(21), 6754–6764.